Abstract
The demand for biopharmaceuticals is increasing, but little progress is being
made to reduce production costs or increase manufacturing capacity. There are
insufficient facilities to cope with the demand for products and new leads in
drug discovery. The use of recombinant plants as factories to express
recombinant proteins has the potential to alleviate this bottleneck. The
production platforms and technologies that enable this are now in place and the
onus is squarely on product development to commercially introduce therapeutics,
and several companies have attracted venture capital sponsorship, and they are
likely to be in a position to achieve this within the next two years.
This Frost & Sullivan strategic analysis service provides an overview of
and outlook for the world plant molecular farming (biofarming) market. The study
provides information on the world industry dynamics with a particular focus on
North America and Europe as major centers of activity in this sector. It also
offers strategic recommendations that enable companies to align their
positioning strategies to benefit from the changing markets and obtain maximum
return on investment.
Transgenic Plants Have the Potential to Improve Biopharmaceutical
Production Efficiency
Biopharmaceutical manufacturers concerns about production capacity can be
eased by investing in new manufacturing technologies and methods such as using
transgenic plants as factories to produce biopharmaceuticals. "The cost of
production can be significantly reduced by producing larger volumes, and
eliminating the need for capital investment in fermentation systems," says
the analyst of this research.
Using microscopic plants such as lemna or moss in bioreactors have the
potential to eliminate containment problems and improve turnover times by
simplifying recombination procedures.
Drug Discovery Market Governed by Regulatory Affairs and Public Perception
Currently, there are no biopharmaceutical products manufactured using plant
molecular farming in the market, with the first products anticipated to reach
the market around 2005-06. However, the U.S. market could be worth $2.20 billion
in 2011, as this emerging sector rapidly gathers pace as public perception and
the regulatory climate improve. Growth is likely to occur fastest between 2008
and 2010 as more products enter the market and receive regulatory approval.
"The gradual relaxation of the unofficial moratorium on transgenic crops
in Europe is a good indication that the public and regulatory perception toward
transgenic crops is improving, and this trend is expected to drive the
market," notes the analyst.
Frost & Sullivan Growth Partnership Service
Based on extensive and in-depth research, real-world consulting work, and new
theories tested in hundreds of companies across many industries, Frost &
Sullivan has evolved its Growth Partnership Services (GPS) program that provides
established and emerging firms with powerful growth visions. Moving beyond token
mission statements, GPS provides an actionable vision to growth consulting
partners by illustrating how key intelligence and strategic research based on
defined goals can guide day-to-day behavior and overall company direction. The
foundation of Frost & Sullivans GPS includes:
- Assisting companies to reach their full potential in the core business
- Providing growth strategies to help companies expand into related
businesses
- Preemptively redefining the core business during market turbulence
- Applying the Frost & Sullivan framework to identify and address common
mistakes resulting from misaligned corporate strategies
- Recommending growth management strategies through continuous partnership
To maximize the potential for growth within a firms internal and external
environment, Frost & Sullivan consultants can facilitate the creation of
strategic programs that deliver improved market success. Frost & Sullivans
strengths lie in combining strategic understanding with market expertise and
applying these with absolute commitment to its clients growth. | 
View Cart
